Richard Marsden
Chief Executive Officer at SYNAIRGEN PLC
Net worth: 64 088 $ as of 2024-03-30
Profile
Richard James Marsden is currently the Chief Executive Officer & Executive Director at Synairgen Plc since 2009.
He is also a Director at Synairgen Research Ltd.
since 2004.
Previously, he worked as the Respiratory Director at MedImmune Ltd.
He was the Managing Director at Southampton Asset Management Ltd.
from 2005 to 2014.
Before that, he served as the Manager-Cystic Fibrosis Business Development at Respironics Ltd.
from 1998 to 2003.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SYNAIRGEN PLC
0.49% | 2022-12-30 | 995,771 ( 0.49% ) | 64 088 $ | 2024-03-30 |
Richard Marsden active positions
| Companies | Position | Start |
|---|---|---|
| SYNAIRGEN PLC | Chief Executive Officer | 2004-05-31 |
Synairgen Research Ltd.
 Synairgen Research Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Synairgen Plc, Synairgen Research Ltd. is a British company that engages in respiratory biology and develops novel therapies. The private company is based in Southampton, UK. Synairgen Research was founded in 2003. | Director/Board Member | 2004-06-06 |
Former positions of Richard Marsden
| Companies | Position | End |
|---|---|---|
Southampton Asset Management Ltd.
 Southampton Asset Management Ltd. Investment ManagersFinance Southampton Asset Management Ltd (SAM) is a venture capital firm, a subsidiary of University of Southampton Holdings Ltd. The firm is headquartered in Southampton, United Kingdom. | Director/Board Member | 2014-03-16 |
Respironics Ltd.
 Respironics Ltd. Financial ConglomeratesFinance Respironics Ltd. develops and manufactures medical and healthcare products. Its products include Porta-Neb, Freeway Freedom, Sidestream, and Ventstream. The company was founded in 1977 and is headquartered in Bognor Regis, the United Kingdom. | Corporate Officer/Principal | 2002-12-31 |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SYNAIRGEN PLC | Health Technology |
| Private companies | 4 |
|---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Respironics Ltd.
Respironics Ltd. Financial ConglomeratesFinance Respironics Ltd. develops and manufactures medical and healthcare products. Its products include Porta-Neb, Freeway Freedom, Sidestream, and Ventstream. The company was founded in 1977 and is headquartered in Bognor Regis, the United Kingdom. | Finance |
Southampton Asset Management Ltd.
Southampton Asset Management Ltd. Investment ManagersFinance Southampton Asset Management Ltd (SAM) is a venture capital firm, a subsidiary of University of Southampton Holdings Ltd. The firm is headquartered in Southampton, United Kingdom. | Finance |
Synairgen Research Ltd.
Synairgen Research Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Synairgen Plc, Synairgen Research Ltd. is a British company that engages in respiratory biology and develops novel therapies. The private company is based in Southampton, UK. Synairgen Research was founded in 2003. | Commercial Services |
- Stock Market
- Insiders
- Richard Marsden
